文献速递血栓与止血

免疫性血小板减少症中静脉注射免疫球蛋白的适用时机

When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?
PubMed 文献 · Br J Haematol · 2024-10-10

该单中心回顾性研究分析了2016至2020年间114例住院患者的208次静脉注射免疫球蛋白(IVIg)治疗,评估其与法国指南的符合性。37%的病例Khellaf评分>8,符合指南;按现行法国指南,84.4%的IVIg处方被判定为合规,不合规处方在年轻患者中更常见(p=0.027)。

要点

  • 法国指南将IVIg限定于有糖皮质激素正式禁忌、Khellaf评分>8或激素抵抗且Khellaf评分≤8等情形。
  • 208次IVIg治疗中37%因Khellaf评分>8符合指南,84.4%的处方经分析判定为合规。
  • 不合规IVIg处方在年轻患者中更常见(p=0.027),合并抗凝治疗也被视为指南外使用理由。

核心结论

  • 按现行法国指南,84.4%的IVIg处方被判定为合规。
  • 不合规IVIg处方在年轻患者中更常见(p=0.027)。
  • 合并抗凝治疗被记录为现行法国指南之外的IVIg处方理由。

研究设计与样本

  • 单中心回顾性研究,纳入2016年至2020年间在本中心住院的114例患者,共208次IVIg治疗。

主要发现

  • 37%的病例Khellaf评分>8,符合法国指南的IVIg处方条件。
  • 其余病例中使用IVIg的原因包括糖皮质激素抵抗(33.7%)、为侵入性操作做准备(8.5%)、妊娠背景(6.6%)和糖皮质激素禁忌(3.3%)。
  • 经分析,84.4%的IVIg处方按现行法国指南判定为合规。
  • 不合规IVIg处方在年轻患者中更常见(p=0.027)。
  • 合并抗凝治疗被记录为现行法国指南之外的IVIg处方理由。

关键数值与推荐

  • 法国指南将IVIg保留用于有糖皮质激素正式禁忌的ITP患者、法国出血评分(Khellaf评分)>8的患者,以及糖皮质激素抵抗且Khellaf评分≤8或正在准备侵入性操作或妊娠期间的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravenous immunoglobulin (IVIg) is the gold standard treatment for severe cases of immune thrombocytopenia (ITP). However, its cost, limited duration of efficacy and market supply tension have led French guidelines to reserve IVIg for ITP patients with formal contra-indications to corticosteroids, with French bleeding score ('Khellaf score') > 8, and corticosteroid-resistant patients either with Khellaf score ≤ 8 or in preparation for an invasive procedure or during pregnancy. We studied the prescribing practices of IVIg for ITP in real-life conditions and assessed their compliance with French guidelines. A monocentric retrospective study was conducted between 2016 and 2020 among 114 patients hospitalized in our unit, for a total of 208 IVIg treatments. In 37% of cases, the Khellaf score was >8, validating IVIg prescription according to French guidelines. In the remaining cases, reasons noted for use of IVIg included corticosteroid resistance (33.7%), preparation for an invasive procedure (8.5%), context of pregnancy (6.6%) and contra-indication to corticosteroids (3.3%). After analysis, IVIg prescription was considered valid according to current French guidelines in 84.4% of cases. Non-compliant IVIg prescription was more frequent in younger patients (p = 0.027). Concomitant anti-coagulation was also noted as an argument for IVIg prescription outside of the current French guidelines.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dubois S, Layese R, Limal N, et al. When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia? Br J Haematol. 2024. PMID: 39389921. doi:10.1111/bjh.19817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。